[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"er-positive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:er-positive":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100659226","blood-biomarkers-for-breast-cancer-treatment-response-100659226",false,"NCT07860866","Blood Biomarkers for Breast Cancer Treatment Response","Prospective Plasma Biomarker Study to Predict 2nd Line Endocrine Therapy Response in ER+ Metastatic Breast Cancer (TrackER)","TrackER","Inclusion Criteria:\n\n1. Patients must be ≥18 years of age\n2. Cytologically or histologically confirmed invasive breast cancer that is:\n\n   1. Clinical stage IV\n   2. HR positive\n   3. Progressing on first line treatment\n3. ECOG 0-2\n4. Locally assessed ER+.\n5. Locally assessed HER2-negative (IHC 2+\u002FFISH-negative or IHC 0 or 1+ \u002Feither FISH-negative or untested).\n6. No prior chemotherapy\n7. Must have the ability to understand and the willingness to sign a written informed consent document.\n8. Must be willing to provide serial blood samples for the study.\n\nExclusion Criteria:\n\n1\\. Medical condition or social situation that may preclude adherence to the protocol.","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","This study looks at whether a simple blood test can help predict how well a breast cancer treatment will work. It follows patients with advanced hormone receptor-positive breast cancer whose cancer has progressed after their first treatment.\n\nResearchers collect a blood sample when patients start a second hormone therapy treatment and may collect additional samples over time. By comparing blood test results with patient outcomes, the study aims to identify biomarkers that can predict which patients are most likely to benefit from treatment.",[25,26],"Breast Cancer (Advanced\u002FMetastatic)","ER Positive",[28,29,30],"ER+ metastatic Breast Cancer","Plasma Biomarker","2nd line Endocrine therapy","NOT_YET_RECRUITING","2026-09-30",{"date":34,"type":35},"2026-10-06","ACTUAL",{"date":37,"type":21},"2026-11-01",{"date":39,"type":21},"2028-05-01",{"name":41,"class":42},"University of Pittsburgh","OTHER"]